Opinion|Videos|June 3, 2024
Alzheimer’s Disease Pipeline
Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please provide an overview of robust Alzheimer’s pipeline and many disease modifying therapies under investigation.
- Discuss novel and emerging treatments that are most advanced in clinical studies or have promising data:
- Valiltramiprosate (ALZ-801,inhibits amyloid oligomer formation, oral)
- ALN-APP (RNAi therapeutic)
- Blarcamesine (sigma-1 and muscarinic receptors ligand)
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Microstructure Imaging has announced that the FDA cleared its MICSI-PET, an MR-guided PET enhancement platform with automated amyloid Centiloid and tau quantification.
Subgroup analyses from the phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, malaise, and cognition in long COVID patients with more severe baseline symptoms.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures
2
Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis
3
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
4
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
5